Carlton Hofferkamp & Jenks Wealth Management LLC Sells 700 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Carlton Hofferkamp & Jenks Wealth Management LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,850 shares of the biopharmaceutical company’s stock after selling 700 shares during the quarter. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Gilead Sciences were worth $583,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Bellevue Group AG grew its stake in Gilead Sciences by 18.2% in the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after purchasing an additional 7,093 shares during the period. Quantinno Capital Management LP grew its stake in shares of Gilead Sciences by 149.5% during the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after acquiring an additional 48,910 shares during the period. McAdam LLC grew its stake in shares of Gilead Sciences by 16.7% during the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock worth $2,344,000 after acquiring an additional 3,627 shares during the period. Capital Investment Advisors LLC grew its stake in shares of Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after acquiring an additional 9,791 shares during the period. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in shares of Gilead Sciences by 3.9% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company’s stock worth $13,132,000 after acquiring an additional 5,382 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on GILD. Barclays increased their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. BMO Capital Markets raised their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Truist Financial raised their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Finally, Oppenheimer raised their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.08.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $17,597,559.49. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 293,356 shares of company stock worth $29,166,240 in the last ninety days. 0.16% of the stock is owned by insiders.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $115.99 on Tuesday. The stock has a market cap of $144.55 billion, a price-to-earnings ratio of 313.49, a P/E/G ratio of 0.71 and a beta of 0.18. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $117.16. The stock’s 50-day moving average is $97.87 and its 200 day moving average is $90.45.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.72%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.